- Home
- OPCH vs TARS Comparison
OPCH vs TARS Comparison
Compare OPCH & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | TARS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPCH | TARS |
|---|---|---|
| Price | $21.44 | $60.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $36.57 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 5.0M | 628.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 48.21 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,998,202,000.00 | $451,360,000.00 |
| Revenue This Year | $7.21 | $56.43 |
| Revenue Next Year | $8.55 | $30.19 |
| P/E Ratio | $72.19 | ★ N/A |
| Revenue Growth | 16.17 | ★ 146.71 |
| 52 Week Low | $18.01 | $38.51 |
| 52 Week High | $36.80 | $85.25 |
Technical Indicators
Market Signals| Indicator | OPCH | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 42.62 |
| Support Level | $19.34 | $60.38 |
| Resistance Level | $29.00 | $67.24 |
| Average True Range (ATR) | 0.89 | 3.63 |
| MACD | 0.39 | 0.13 |
| Stochastic Oscillator | 71.94 | 34.77 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.